Oncolytics Biotech Stock Price - ONCY

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
SMALL CAP BASIC
Monthly Subscription
for only
$33.03
VAT not included
After Hours
Last Trade
Last: $ 0.65 ▲ 0.02 (3.17%)
Company Name Stock Ticker Symbol Market Type
Oncolytics Biotech ONCY NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.088 16.24% 0.63 0.7351 0.55001 0.6235 0.542 23:59:54
Bid Price Ask Price Spread Spread % News
0.65 0.70 0.05 7.14% 3 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,772 1,266,046 $ 0.614610 $ 778,125 244,534 0.53 - 5.12
Last Trade Time Type Quantity Stock Price Currency
17:46:03 formt 2,041 $ 0.65 USD

Oncolytics Biotech Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 12.85M 20.39M $ -17.04M -0.78 - 24.98M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Oncolytics Biotech News

Loading Messages....

Latest ONCY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCY Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week11.030.530.6332693k-0.37-37.00%
1 Month1.621.710.530.7853290k-0.99-61.11%
3 Months1.92.010.530.9940130k-1.27-66.84%
6 Months2.012.370.531.4200113k-1.38-68.66%
1 Year4.46165.11990.531.991690k-3.8316-85.88%
3 Years5.857.40.532.492586k-5.22-89.23%
5 Years5.857.40.532.492586k-5.22-89.23%

Oncolytics Biotech Description

Oncolytics Biotech Inc is a development stage biotechnology company. It focuses on discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its main product is Reolysin. The company also has patents issued worldwide, mainly in US and Canada. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.